Dr. Pal (US) talks about his ASCO GU21 presentation “Sunitinib versus cabozantinib, crizotinib or savolitinib in metastatic papillary renal cell carcinoma (pRCC): Results from the randomized phase II SWOG 1500 study”.
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.I agreeRead More
